Du är här

2016-05-16

Cantargia AB: Cantargia interim report January - March 2016

Cantargia AB's ("Cantargia") interim report for January - March 2016
is available on the company website
(www.cantargia.com/Investors/Reports).

Significant events in the first quarter

· Approval from the European Patent Office (EPO) of Cantargia's
patent application for IL1RAP as target for antibody therapy and
diagnostics of several types of solid tumours, and patent approvals
in Australia, Japan and Mexico for use of IL1RAP as target molecule
for antibody treatment of hematological malignancies.

· The second toxicity study of the CAN04 product candidate showed
that the treatment did not produce any negative effects on repeated
treatment with clinically relevant doses and the results further
support the impression that CAN04 will have a good safety in
patients.

· Cantargia's CEO Göran Forsberg made a number of presentations of
the Company both internationally and in Sweden.

Significant events after the end of the period

· The company raised approximately SEK 31.4 million before issue
costs, through the exercise of warrants of series TO 1 and TO 3.

· An investor presentation at the international BioEquity conference
in Copenhagen was given on 10 May 2016 and one will be given at the
Småbolagsdagen small cap investor event at Sheraton Stockholm Hotel
on 13 June 2016.

· The annual report for the financial year 2015 was published on 29
April 2016 and is available for download on the Company's website,
www.cantargia.com.

Financial information

First quarter (1 Jan 2016 - 31 Mar 2016)

· Other operating revenue was kSEK 0 (0).
· Earnings after financial items were kSEK -8,097 (-3,627).
· Earnings per share were approximately SEK -0.60 (-0.27).
· The equity/assets ratio was around 78 (89) per cent compared with
the beginning of the year.

Definitions

· Earnings per share: Profit for the period divided by 13,505,874
shares as of 31 March 2016. It should be noted that the number of
shares increased by 4,127,260 after the end of the period as a result
of the exercise of warrants of series TO 1 and TO 3. Following
registration with the Swedish Companies Registration Office, the
total number of shares of Cantargia is 17,633,134.

· Equity/assets ratio: Equity divided by total capital.
· Unless otherwise indicated, figures in parentheses refer the same
period in the previous year.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com

-----------------------------------------------------------
http://news.cision.com/cantargia-ab/r/cantargia-interim-report-january--...
http://mb.cision.com/Main/7470/2009429/515873.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.